Centhaquine

Cardiovascular medication
  • In general: ℞ (Prescription only)
Identifiers
  • 2-[2-[4-(3-Methylphenyl)piperazin-1-yl]ethyl]quinoline
CAS Number
  • 57961-90-7
PubChem CID
  • 162163
DrugBank
  • DB16122
UNII
  • QD4VI0J9T5
ChEMBL
  • ChEMBL4594437
CompTox Dashboard (EPA)
  • DTXSID40206680 Edit this at Wikidata
Chemical and physical dataFormulaC22H25N3Molar mass331.463 g·mol−13D model (JSmol)
  • Interactive image
  • CC1=CC(=CC=C1)N2CCN(CC2)CCC3=NC4=CC=CC=C4C=C3
InChI
  • InChI=InChI=1S/C22H25N3/c1-18-5-4-7-21(17-18)25-15-13-24(14-16-25)12-11-20-10-9-19-6-2-3-8-22(19)23-20/h2-10,17H,11-16H2,1H3
  • Key:UJNWGFBJUHIJKK-UHFFFAOYSA-N

Centhaquine (brand name Lyfaquin) is a cardiovascular drug.[1] In India, it is approved for the treatment of hypovolemic shock.[2]

Centhaquine is a vasopressor acting on α2A- and α2B-adrenoreceptors.[3] It increases venous return and improves tissue perfusion.

References

  1. ^ Gulati A, Jain D, Agrawal NR, Rahate P, Choudhuri R, Das S, et al. (June 2021). "Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Controlled Trial". Advances in Therapy. 38 (6): 3223–3265. doi:10.1007/s12325-021-01760-4. PMC 8189997. PMID 33970455.
  2. ^ "Marketing authorization received for Lyfaquin (centhaquine) to treat patients with hypovolemic shock from Indian regulatory agency" (Press release). May 14, 2020. Archived from the original on August 9, 2022. Retrieved April 25, 2024.
  3. ^ Chalkias A, Pais G, Gulati A (March 2024). "Effect of Centhaquine on the Coagulation Cascade in Normal State and Uncontrolled Hemorrhage: A Multiphase Study Combining Ex Vivo and In Vivo Experiments in Different Species". International Journal of Molecular Sciences. 25 (6): 3494. doi:10.3390/ijms25063494. PMC 10970680. PMID 38542464.
  • v
  • t
  • e